Biotronik has shared new data presented at EuroPCR 2022 (17–20 May, Paris, France) focused on the on the safety profile of its Magmaris resorbable magnesium scaffold (RMS) system.

Late-breaking trial data presented at EuroPCR 2022 (17–20 May, Paris, France) underscore the potential of renal denervation as an adjunctive therapy to treat hypertension, complementing existing first-line treatments including lifestyle modifications and medication, attendees of the conference heard.

Medtronic has announced that it has received US Food and Drug Administration (FDA) approval for the Onyx Frontier drug-eluting stent (DES).

A US analysis comparing trends in transcatheter and surgical mitral valve repair (SMVR) has found a “significant” increase in the use of transcatheter edge-to-edge repair (TEER) relative to the use of SMVR in recent years.

At the 2022 Charing Cross (CX) International Symposium (26–28 April, London, UK), Tom Carrell (Cydar Medical, Barrington, UK) delivered a Podium 1st presentation titled “Making endovascular aortic repair outcomes more predictable: Artificial intelligence [AI] takes on a 20-year-old challenge”.

Biosensors International Group has announced both the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approval for BioFreedom Ultra and US Food and Drug Administration (FDA) approval for BioFreedom.  

Surmodics has announced that its Pounce thrombectomy system achieved 100% technical success in 20 first-in-human (FIH) procedures. The FIH data were presented by Gary Ansel (Columbus, USA) at the 2022 Charing Cross (CX) Symposium (26–28 April, London, UK).

Corindus, a Siemens Healthineers company, announced today the opening of its new headquarters at 275 Grove Street in Newton, USA. Siemens Healthineers relocated the Corindus headquarters from its previous location in Waltham, USA to accommodate company growth, doubling the size of the current location from 35,000 to 77,000 square feet, according to a company press release.

Life has not slowed for Patricia Harden of Oakland, California, since she sold her public relations company in 2020 or since retiring from her remaining consulting work the following year. Now 73, she's serving on the board of nonprofits, taking part in a writing group and doing Pilates.

Miracor Medical has announced the first patient enrolled in the PICSO-AMI-V study to evaluate PiCSO—pressure-controlled intermittent coronary sinus occlusion—therapy as an adjunct to conventional primary percutaneous coronary intervention (PCI) for patients presenting with inferior ST-Elevation Myocardial Infarction (STEMI).

Investigators have completed enrolment in the RADIANCE-II pivotal trial of the Paradise ultrasound renal denervation (uRDN, Recor Medical) system for the treatment of uncontrolled hypertension.

Carmat, designer and developer of an advanced total artificial heart, has issued an update on its activities and outlook—confirming that its new implantable prostheses will be available in October 2022.